NCT06654947 2024-12-16
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Fujian Cancer Hospital
National Cancer Center, Korea
National Cancer Center, Korea
National Cancer Center, Korea